Antiseptics, with a broader spectrum of antimicrobial efficacy, lower risk of antibiotic resistance development, and minimal collateral damage to host tissues, are important alternatives to control the bioburden in wounds. Povidone iodine (PVP-I), in use for several decades, has the broadest spectrum of activity, a persistent antimicrobial effect, an ability to penetrate biofilms, and a lack of acquired or cross-resistance. It demonstrates good skin tolerance and low cytotoxicity. However, some reports on PVP-I have raised concerns over allergy, ineffective penetration, and toxic effects on host cells. The majority of these concerns are based on in vitro or rodent wound studies with diverse study designs and outcomes; these results may not be directly applicable in the clinical reality in humans. In this paper, we discuss the efficacy and safety of PVP-I and outline its place in wound healing in Asia, based on an appraisal of recent literature and clinical practice across the region.

Keywords:
Povidone iodine, Wound healing, Antiseptic, Antimicrobial agents
1.
Vowden K, Vowden M, Carville K: Antimicrobials made easy. Wounds Int 2011;2:1-6.
2.
White RJ, Cutting K, Kingsley A: Topical antimicrobials in the control of wound bioburden. Ostomy Wound Manage 2006;52:26-58.
3.
Sibbald R, Leaper D, Queen D: Iodine made easy. Wounds Int 2011;2:1-6.
4.
Brånemark PI, Albrektsson B, Lindström J, Lundborg G: Local tissue effects of wound disinfectants. Acta Chir Scand 1966;357:166-176.
5.
Khan MN, Naqvi AH: Antiseptics, iodine, povidone iodine and traumatic wound cleansing. J Tissue Viability 2006;16:6-10.
6.
Lineaweaver W, Howard R, Soucy D, McMorris S, Freeman J, Crain C, et al: Topical antimicrobial toxicity. Arch Surg 1985;120:267-270.
7.
Rodeheaver G, Bellamy W, Kody M, Spatafora G, Fitton L, Leyden K, Edlich R: Bactericidal activity and toxicity of iodine-containing solutions in wounds. Arch Surg 1982;117:181-186.
8.
Banwell H: What is the evidence for tissue regeneration impairment when using a formulation of PVP-I antiseptic on open wounds? Dermatology 2006;212(suppl 1):66-76.
9.
Vermeulen H, Westerbos SJ, Ubbink DT: Benefit and harm of iodine in wound care: a systematic review. J Hosp Infect 2010;76:191-199.
10.
Atiyeh BS, Dibo SA, Hayek SN: Wound cleansing, topical antiseptics and wound healing. Int Wound J 2009;6:420-430.
11.
Lachapelle JM, Castel O, Casado AF, Leroy B, Micali G, Tennstedt D, et al: Antiseptics in the era of bacterial resistance: a focus on povidone iodine. Clin Pract 2013;10:579-592.
12.
Lai CC, Lee K, Xiao Y, Ahmad Y, Ahmad N, Veeraraghavan B, et al: High burden of antimicrobial drug resistance in Asia. J Glob Antimicrob Resist 2014;2:141-147.
13.
Daeschlein G: Antimicrobial and antiseptic strategies in wound management. Int Wound J 2013;10:9-14.
14.
Gottrup F, Apelqvist J, Bjarnsholt T, Cooper R, Moore Z, Peters EJ, et al: EWMA document: antimicrobials and non-healing wounds. Evidence, controversies and suggestions. J Wound Care 2013;22:1-89.
15.
Leaper D, McBain AJ, Kramer A, Assadian O, Sanchez JL, Lumio J, et al: Healthcare associated infection: Novel strategies and antimicrobial implants to prevent surgical site infection. Ann R Coll Surg Engl 2010;92:453-568.
16.
Lipsky BA, Hoey C: Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis 2009;49:1541-1549.
17.
Angel DE, Morey P, Storer JG, Mwipatayi BP: The great debate over iodine in wound care continues: a review of the literature. Wound Pract Res 2008;16:6-21.
18.
Durani P, Leaper D: Povidone-iodine: use in hand disinfection, skin preparation and antiseptic irrigation. Int Wound J 2008;5:376-387.
19.
Selvaggi G, Monstrey S, Van Landuyt K, Hamdi M, Blondeel P: The role of iodine in antisepsis and wound management: a reappraisal. Acta Chir Belg 2003;103:241-247.
20.
Percival SL, Finnegan S, Donelli G, Vuotto C, Rimmer S, Lipsky BA: Antiseptics for treating infected wounds: efficacy on biofilms and effect of pH. Crit Rev Microbiol 2016;42:293-309.
21.
Reimer K, Wichelhaus TA, Schäfer V, Rudolph P, Kramer A, Wutzler P, et al: Antimicrobial effectiveness of povidone-iodine and consequences for new application areas. Dermatology 2002;204(suppl 1):114-120.
22.
Kunisada T, Yamada K, Oda S, Hara O: Investigation on the efficacy of povidone-iodine against antiseptic-resistant species. Dermatology 1997;195(suppl 2):14-18.
23.
Yasuda T, Yoshimura Y, Takada H, Kawaguchi S, Ito M, Yamazaki F, Iriyama J, Ishigo S, Asano Y: Comparison of bactericidal effects of commonly used antiseptics against pathogens causing nosocomial infections. Part 2. Dermatology 1997;195(suppl 2):19-28.
24.
Hoekstra MJ, Westgate SJ, Mueller S: Povidone-iodine ointment demonstrates in vitro efficacy against biofilm formation. Int Wound J 2017;14:172-179.
25.
Hill KE, Malic S, McKee R, Rennison T, Harding KG, Williams DW, et al: An in vitro model of chronic wound biofilms to test wound dressings and assess antimicrobial susceptibilities. J Antimicrob Chemother 2010;65:1195-1206.
26.
Ventola CL: The antibiotic resistance crisis. Part 1. Causes and threats. P T 2015;40:277-283.
27.
Kang CI, Song JH: Antimicrobial resistance in Asia: current epidemiology and clinical implications. Infect Chemother 2013;45:22-31.
28.
Demling RH, Waterhouse B: The increasing problem of wound bacterial burden and infection in acute and chronic soft-tissue wounds caused by methicillin-resistant Staphylococcus aureus. J Burns Wounds 2007;7:e8.
29.
Poovelikunnel T, Gethin G, Humphreys H: Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother 2015;70:2681-2692.
30.
Leaper DJ, Durani P: Topical antimicrobial therapy of chronic wounds healing by secondary intention using iodine products. Int Wound J 2008;5:361-368.
31.
McKenna PJ, Lehr GS, Leist P, et al: Antiseptic effectiveness with fibroblast preservation. Ann Plast Surg 1991;27:265-268.
32.
McLure AR, Gordon J: In-vitro evaluation of povidone-iodine and chlorhexidine against methicillin-resistant Staphylococcus aureus. J Hosp Infect 1992;21:291-299.
33.
Niedner R: Cytotoxicity and sensitization of povidone-iodine and other frequently used anti-infective agents. Dermatology 1997;195(suppl 2):89-92.
34.
Langer S, Botteck NM, Bosse B, Reimer K, Vogt PM, Steinau HU, et al: Effect of polyvinylpyrrolidone-iodine liposomal hydrogel on wound microcirculation in SKH1-hr hairless mice. Eur Surg Res 2006;38:27-34.
35.
Kjolseth D, Frank JM, Barker JH, Anderson GL, Rosenthal AI, Acland RD, et al: Comparison of the effects of commonly used wound agents on epithelialization and neovascularization. J Am Coll Surg 1994;179:305-312.
36.
Gravett A, Sterner S, Clinton JE, Ruiz E: A trial of povidone-iodine in the prevention of infection in sutured lacerations. Ann Emerg Med 1987;16:167-171.
37.
Stringer MD, Lawrence JC, Lilly HA: Antiseptics and the casualty wound. J Hosp Infect 1983;4:410-412.
38.
Sindelar WF, Mason GR: Irrigation of subcutaneous tissue with povidone-iodine solution for prevention of surgical wound infections. Surg Gynecol Obstet 1979;148:227-231.
39.
Vilijanto J: Disinfection of surgical wounds without inhibition of normal wound healing. Arch Surg 1980;115:253-256.
40.
Lee BY, Trainor FS, Thoden WR: Topical application of povidone-iodine in the management of decubitus and stasis ulcers. J Am Geriatr Soc 1979;27:302-306.
41.
Fumal I, Braham C, Paquet P, Piérard-Franchimont C, Piérard GE: The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study. Dermatology 2002;204(suppl 1):70-74.
42.
Daróczy J: Antiseptic efficacy of local disinfecting povidone-iodine (Betadine) therapy in chronic wounds of lymphedematous patients. Dermatology 2002;204(suppl 1):75-78.
43.
Woo KY: Management of non-healable or maintenance wounds with topical povidone iodine. Int Wound J 2014;11:622-626.
44.
Han KH, Maitra AK: Management of partial skin thickness burn wounds with Inadine dressings. Burns 1989;15:399-402.
45.
Homann HH, Rosbach O, Moll W, Vogt PM, Germann G, Hopp M, et al: A liposome hydrogel with polyvinyl-pyrrolidone iodine in the local treatment of partial-thickness burn wounds. Ann Plast Surg 2007;59:423-427.
46.
Vogt PM, Hauser J, Rossbach O, Bosse B, Fleischer W, Steinau HU, et al: Polyvinyl pyrrolidone-iodine liposome hydrogel improves epithelialization by combining moisture and antisepsis: a new concept in wound therapy. Wound Repair Regen 2001;9:116-122.
47.
Vogt PM, Reimer K, Hauser J, Rossbach O, Steinau HU, Bosse B: PVP-iodine in hydrosomes and hydrogel-A novel concept in wound therapy leads to enhanced epithelialization and reduced loss of skin grafts. Burns 2006;32:698-705.
48.
Al-Kaisy AA, Sahib AS, Hussain SA, Hussain HA: Pre- and post-operative prophylactic use of local povidone-iodine in potentially contaminated surgery. Libyan J Med Res 2010;7:100-105.
49.
deKock M: Topical burn therapy comparing povidone-iodine ointment or cream plus aserbine, and povidone-iodine cream. J Hosp Infect 1985;6(suppl A):127-132.
50.
Eming SA, Smola-Hess S, Kurschat P, Hirche D, Krieg T, Smola H: A novel property of povidon-iodine: inhibition of excessive protease levels in chronic non-healing wounds. J Invest Dermatol 2006;126:2731-2733.
51.
Georgiade NG, Harris WA: Open and closed treatment of burns with povidone-iodine. Plast Reconstr Surg 1973;52:640-644.
52.
Lammers RL, Fourre M, Vallaham ML, et al: Effect of povidone-iodine and saline soaking on bacterial counts in acute, traumatic, contaminated wounds. Ann Emerg Med 1990;19:709-714.
53.
Lineaweaver WL, McMorris S, Soucy D, et al: Cellular and bacterial toxicities of topical antimicrobials. Plast Reconstr Surg 1985;75:394.
54.
Piérard-Franchimont C, Paquet P, Arrese JE, et al: Healing rate and bacterial necrotizing vasculitis in venous leg ulcers. Dermatol 1997;194:383-387.
55.
Vehmeyer-Heeman M, Van den Kerckhove E, Gorissen K, Boeckx W: Povidone-iodine ointment: no effect of split skin graft healing time. Burns 2005;31:489-494.
56.
de Jonge SW, Boldingh QJJ, Solomkin JS, Allegranzi B, Egger M, Dellinger EP, Boermeester MA: Systematic review and meta-analysis of randomized controlled trials evaluating prophylactic intra-operative wound irrigation for the prevention of surgical site infections. Surg Infect (Larchmt) 2017;18:508-519.
57.
Liu JX, Werner JA, Buza JA 3rd, Kirsch T, Zuckerman JD, Virk MS: Povidone-iodine solutions inhibit cell migration and survival of osteoblasts, fibroblasts, and myoblasts. Spine (Phila Pa 1976) 2017, DOI: 10.1097/BRS.0000000000002224.
58.
Norman G, Dumville JC, Moore ZE, Tanner J, Christie J, Goto S: Antibiotics and antiseptics for pressure ulcers. Cochrane Database Syst Rev 2016;4:CD011586.
59.
O'Meara S, Al-Kurdi D, Ologun Y, Ovington LG: Antibiotics and antiseptics for venous leg ulcers. Cochrane Database Syst Rev 2010;1: CD003557.
60.
Privitera GP, Costa AL, Brusaferro S, Chirletti P, Crosasso P, Massimetti G, Nespoli A, Petrosillo N, Pittiruti M, Scoppettuolo G, Tumietto F, Viale P: Skin antisepsis with chlorhexidine versus iodine for the prevention of surgical site infection: a systematic review and meta-analysis. Am J Infect Control 2017;45:180-189.
61.
Shukrimi A, Sulaiman AR, Halim AY, Azril A: A comparative study between honey and povidone iodine dressing solution for Wagner type 2 diabetic foot ulcer. Med J Malaysia 2008;63:44-46.
62.
Burks RI: Povidone-iodine solution in wound treatment. Phys Ther 1998;78:212-218.
63.
Van den Broek PJ, Buys LF, Van Furth R: Interaction of povidone-iodine compounds, phagocytic cells, and microorganisms. Antimicrob Agents Chemother 1982;22:593-597.
64.
Tatnall FM, Leigh IM, Gibson JR: Assay of antiseptic agents in cell culture: conditions affecting cytotoxicity. J Hosp Infect 1991;17:287-296.
65.
Goldenheim PD: An appraisal of povidone-iodine and wound healing. Postgrad Med J 1993;69(suppl 3):S97-S105.
66.
Lachapelle JM: A comparison of the irritant and allergenic properties of antiseptics. Eur J Dermatol 2014;24:3-9.
67.
Lachapelle JM: Allergic contact dermatitis from povidone-iodine: a re-evaluation study. Contact Dermatitis 2005;52:9-10.
68.
Brockow K, Christiansen C, Kanny G, Clément O, Barbaud A, Bircher A, et al: Management of hypersensitivity reactions to iodinated contrast media. Allergy 2005;60:150-158.
69.
Dewachter P, Mouton-Faivre C: Allergy to iodinated drugs and to foods rich in iodine: Iodine is not the allergenic determinant (in French). Presse Med 2015;44:1136-1145.
70.
Dooms-Goossens A, Deveylder H, de Alam AG, Lachapelle JM, Tennstedt D, Degreef H: Contact sensitivity to nonoxynols as a cause of intolerance to antiseptic preparations, J Am Acad Dermatol 1989;21:723-727.
71.
Gunjan K, Shobha C, Sheetal C, Nanda H, Vikrant C, Chitnis DS: A comparative study of the effect of different topical agents on burn wound infections. Indian J Plast Surg 2012;45:374-378.
72.
Dodds Ashley ES, Kaye KS, DePestel DD, Hermsen ED: Antimicrobial stewardship: philosophy versus practice. Clin Infect Dis 2014;59(suppl 3):S112-S121.
73.
Tamma PD, Srinivasan A, Cosgrove SE: Infectious Disease Clinics of North America. Antimicrobial stewardship. Preface. Infect Dis Clin North Am 2014;28:xi-xii.
74.
Ford SJ, Bigliardi PL, Sardella TC, Urich A, Burton NC, Kacprowicz M, et al: Structural and functional analysis of intact hair follicles and pilosebaceous units by volumetric multispectral optoacoustic tomography. J Invest Dermatol 2016;136:753-761.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.